United States Patent 5,605,690: Claim Scope, Strength, and TNF-Receptor/Chimeric Antibody Landscape

United States Patent 5,605,690 (“’690”) claims therapeutic TNF antagonists built around a specific TNF receptor protein fragment (amino acids 3-163 of SEQ ID NO:1) used either directly as a receptor or after fusion to an immunoglobulin constant domain, with methods limited to lowering “active TNF-α” in mammals and to arthritis settings.

What exactly does US 5,605,690 claim?

Claim set structure

The patent has six independent-to-semi-independent method claims that differ by (i) whether the antagonist is a receptor fragment or a chimeric antibody and (ii) whether the target indication is general TNF-α lowering or arthritis.

Core TNF antagonist definition used across claims

TNF receptor fragment: “a TNF receptor comprising the sequence of amino acids 3-163 of SEQ ID NO:1” (claims 1, 2, 4, 5).
Chimeric antibody: “a chimeric antibody comprising a TNF receptor comprising the sequence of amino acids 3-163 of SEQ ID NO:1 fused to the constant domain of an immunoglobulin molecule” (claims 1, 3, 4, 6).

Method framing

Generic: “lowering the levels of active TNF-α in a mammal in need thereof” (claims 1-3).
Arthritis: “lowering the levels of active TNF-α in a mammal having arthritis” (claims 4-6).

Plain-English claim elements

All method claims share the following required elements:

Identify a mammal (the preamble).
A TNF-α lowering goal is stated as “lowering levels of active TNF-α.”
Administer a “TNF-lowering amount” / “therapeutically effective amount.”
The administered agent is limited to one of two structures:
- (a) TNF receptor fragment consisting of amino acids 3-163 of SEQ ID NO:1, or
- (b) a chimeric antibody where that receptor fragment is fused to an immunoglobulin constant domain.

Claim-by-claim mapping

Claim	Indication framing	TNF antagonist scope
1	Mammal “in need thereof”	Either (a) receptor fragment (aa 3-163 of SEQ ID NO:1) or (b) receptor fragment fused to Ig constant domain
2	Mammal “in need thereof”	Receptor fragment only (aa 3-163 of SEQ ID NO:1)
3	Mammal “in need thereof”	Chimeric antibody only (aa 3-163 fused to Ig constant domain)
4	Mammal having arthritis	Either receptor fragment or chimeric antibody
5	Mammal having arthritis	Receptor fragment only
6	Mammal having arthritis	Chimeric antibody only

Critical scope observation: claim type is methods, not compositions

The claims are method claims that focus on administration and TNF-α lowering outcomes. The identity of the administered agent is constrained by sequence content and fusion architecture, but there is no independent composition claim in the text you provided.

That matters for enforcement: proving infringement hinges on use/administration in a claimed setting (mammal in need thereof, or arthritis) and the agent meeting the structural definition (aa 3-163 of SEQ ID NO:1; with Ig constant fusion only for the chimeric antibody branch).

How strong are the claims against likely TNF competitors?

What the patent pins down

This patent narrows the TNF antagonist design in two ways:

Sequence constraint: it is not “any TNF receptor,” but specifically a receptor “comprising” the amino acids 3-163 of SEQ ID NO:1.
Architectural constraint for the antibody branch: for the chimeric antibody, the receptor fragment must be fused to the constant domain of an immunoglobulin molecule.

If a competing biologic changes the fragment boundary, uses a different receptor domain range, or alters the fusion architecture away from “constant domain” fusion, it can fall outside the literal sequence/fusion language, depending on how “comprising” is interpreted in practice.

Key vulnerability: “comprising” can broaden, but the anchor is still specific

“Comprising” typically allows additional sequences around the recited fragment. That can broaden coverage if a competitor includes aa 3-163 inside a larger TNF-binding scaffold. But the claim still requires that the administered TNF antagonist includes the specified receptor fragment.

A competitor that uses:

a different TNF receptor fragment boundary (not containing aa 3-163 as recited),
a different TNF-binding moiety (not based on SEQ ID NO:1 fragment 3-163),
a different fusion type (not a fusion to an Ig constant domain), may avoid literal coverage.

Key vulnerability: “active TNF-α” is an outcome phrasing, not a measuring method

The claims require lowering “levels of active TNF-α,” but they do not recite assay conditions, pharmacodynamic thresholds, or specific biomarkers.

That can cut both ways:

It simplifies proof for a patentee if clinical/biomarker evidence shows reduction of active TNF-α after administration.
It can also allow a defendant to argue non-infringement by showing that the marketed product primarily neutralizes total TNF-α, binds inactive forms, or lacks measurable reduction of “active TNF-α” as defined in the patent context.

In practice, most litigated TNF receptor antagonists use similar receptor-binding and neutralization rationales, so outcome phrases often track broadly to what the mechanism does.

How does this patent fit into the historical TNF antagonist landscape?

Landscape framing: receptor-based TNF antagonism

The ’690 claim language targets a TNF receptor fragment and an Ig-fusion version, which places it in the receptor-derived TNF neutralization lineage that produced receptor fusion therapeutics and related constructs.

The competitive space is anchored around:

soluble TNF receptors (receptor fragments or engineered soluble forms),
TNF receptor-Ig fusions (chimeric antibodies or fusion proteins),
anti-TNF monoclonals (neutralizing antibodies against TNF-α itself).

The ’690 claim set is structurally aligned to receptor-based antagonists, not anti-TNF antibodies.

Where the risk typically sits

Against receptor-Ig constructs that use the same (or a substantially identical) receptor fragment and Ig constant fusion architecture, ’690 creates credible claim coverage.

Against anti-TNF monoclonals that do not incorporate the recited receptor fragment, the claims are typically not directly aimed at those agents.

What is the likely infringement theory for a receptor-Ig TNF antagonist?

Literal infringement pathway (receptor-Ig)

A plausible infringement theory runs as follows:

The accused biologic is administered to a mammal meeting the claimed preamble (a mammal in need thereof, or arthritis patients).
The biologic contains a TNF receptor sequence that includes amino acids 3-163 of SEQ ID NO:1.
The biologic is configured as (for chimeric antibody branch) a fusion of that receptor fragment to an immunoglobulin constant domain.
Administration lowers “active TNF-α” levels.

Claims 1, 3, 4, 6 are most aligned with this theory.

Literal infringement pathway (receptor fragment alone)

If an accused product is a soluble receptor fragment that contains the same aa 3-163 segment (without Ig constant fusion), then claims 1, 2, 4, 5 are the closest targets.

Doctrine of equivalents pressure point

If competitors avoid literal “amino acids 3-163” by minor boundary shifts or by inserting additional residues, the doctrine of equivalents can become relevant, particularly if the accused structure performs substantially the same TNF receptor binding function and the difference is insubstantial.

However, equivalence is constrained by prosecution history estoppel and by prior art scope; those specifics are not included in what you provided, so only structural risks can be assessed from claim text alone.

Where are the biggest prior-art and claim-narrowing pressure points?

Sequence- and domain-level prior art

Because the claims are heavily anchored to:

SEQ ID NO:1 amino acids 3-163, and
Ig constant domain fusion for the chimeric antibody, the most relevant prior art is likely:
earlier TNF receptor fragment constructs,
earlier TNF receptor fusion proteins,
earlier engineered soluble receptor forms used therapeutically.

If earlier patents disclosed:

the same or near-identical receptor fragment boundary,
the same Ig constant fusion arrangement, and were enabling for the method use (lowering active TNF-α and/or arthritis indication), then validity risks rise sharply.

Method claim novelty

Method claims tend to be vulnerable if:

administration of receptor-based TNF antagonists for TNF reduction was already known,
and the only novelty is the agent definition already disclosed in the art.

Here, the agent definition is very specific. That specificity can preserve novelty if the fragment boundary and fusion architecture were not previously disclosed in one enabling teaching.

How does 5,605,690 differentiate from anti-TNF monoclonals?

The claims are limited to TNF antagonists “selected from” the receptor fragment and receptor-Ig chimeric antibodies described.

Anti-TNF monoclonals typically bind TNF-α directly and do not contain:

a TNF receptor sequence matching SEQ ID NO:1 fragment 3-163,
nor an Ig constant fusion of a TNF receptor fragment in the claimed sense.

So, the strongest coverage is against receptor-based antagonists and receptor-Ig constructs, not against antibody-only TNF blockade products.

What does this mean for the modern TNF competitor set?

Direct-coverage zone

Products that are:

receptor fragment based, with the aa 3-163 segment,
and receptor fragment fused to an immunoglobulin constant domain for the chimeric antibody version, fall into the highest-risk area for the claim set.

Lower coverage zone

Products that are:

TNF-neutralizing antibodies not incorporating the TNF receptor fragment,
receptor constructs based on different receptor domains (different boundaries),
receptor fusions using non-constant domain fusion architectures, should sit outside the literal language.

Patent landscape analytics: practical licensing and design-around levers

Below are the concrete levers implied by the claim language:

Design-around levers (agent structure)

Claim anchor	Design-around lever
“sequence of amino acids 3-163 of SEQ ID NO:1”	Use a TNF receptor fragment that does not include exactly that aa 3-163 as recited (or lacks substantial identity to it under infringement tests)
“fused to the constant domain of an immunoglobulin molecule”	Use a fusion architecture that does not fuse the receptor fragment to an Ig constant domain as claimed (different Fc design, different junction architecture)
Receptor vs chimeric antibody split	Market and justify one configuration only; keep the other architecture from matching a specific branch

Commercial and enforcement levers (use context)

Claim anchor	Enforcement lever
“mammal in need thereof”	Broad enough to capture most chronic TNF therapy use contexts in which TNF-α lowering occurs
“mammal having arthritis”	Narrows to arthritis indications for claims 4-6; reduces risk if product use is limited to non-arthritis indications

For licensing strategy, the receptor fragment version (claims 2 and 5) and the receptor-Ig chimeric antibody version (claims 3 and 6) operate as distinct commercial risk buckets.

Key Takeaways

US 5,605,690 is a TNF reduction method patent that targets administration of a TNF receptor fragment defined by amino acids 3-163 of SEQ ID NO:1, and a chimeric antibody where that fragment is fused to an immunoglobulin constant domain.
The claims split into receptor fragment only versus receptor-Ig chimeric antibody, and into general TNF-α lowering versus arthritis.
The strongest enforcement path is against products that contain the same SEQ ID NO:1 fragment (3-163) and, for the antibody branch, use Ig constant domain fusion.
The sharpest design-around lever is changing fragment boundaries or fusion architecture so that the administered agent no longer meets the claim’s sequence and fusion requirements.
Anti-TNF monoclonals that do not include the recited TNF receptor fragment are structurally misaligned with the claim scope.

FAQs

Do the claims require a specific dosing regimen or pharmacodynamic threshold?
No. The claims require administering a “TNF-lowering amount” / “therapeutically effective amount,” without reciting assay thresholds or dosing schedules.
Are the claims limited to arthritis only?
No. Claims 1-3 cover mammals “in need thereof,” while claims 4-6 restrict to arthritis.
Does claim 1 cover both the receptor fragment and the chimeric antibody?
Yes. Claim 1 selects either the receptor fragment (aa 3-163 of SEQ ID NO:1) or the receptor-Ig chimeric antibody (same fragment fused to an Ig constant domain).
What is the main structural limitation for infringement?
Presence of the TNF receptor sequence comprising amino acids 3-163 of SEQ ID NO:1, and for the chimeric antibody branch, fusion of that fragment to an immunoglobulin constant domain.
How would an anti-TNF antibody typically fare versus these claims?
If it does not incorporate the specified TNF receptor fragment and Ig constant fusion architecture, it is less likely to fall within the literal claim language.

References

[1] United States Patent 5,605,690. (claims text as provided).

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Immunex Corporation	ENBREL	etanercept	For Injection	103795	November 02, 1998	⤷ Start Trial	2015-02-08
Immunex Corporation	ENBREL	etanercept	For Injection	103795	May 27, 1999	⤷ Start Trial	2015-02-08
Immunex Corporation	ENBREL	etanercept	Injection	103795	September 27, 2004	⤷ Start Trial	2015-02-08
Immunex Corporation	ENBREL	etanercept	Injection	103795	February 01, 2007	⤷ Start Trial	2015-02-08
Immunex Corporation	ENBREL MINI	etanercept	Injection	103795	September 14, 2017	⤷ Start Trial	2015-02-08
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Country	Patent Number	Estimated Expiration
South Africa	907072	⤷ Start Trial
World Intellectual Property Organization (WIPO)	9406476	⤷ Start Trial
World Intellectual Property Organization (WIPO)	9319777	⤷ Start Trial
World Intellectual Property Organization (WIPO)	9103553	⤷ Start Trial
United States of America	RE36755	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Patent: 5,605,690

Summary for Patent: 5,605,690